Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol.
Daniel I BrierleyJoe R HarmanNatasha GiallourouEmma LeishmanAnna Emily RoashanBen A D MellowsHeather B BradshawJonathan R SwannKetan PatelBenjamin J WhalleyClaire Michelle WilliamsPublished in: Journal of cachexia, sarcopenia and muscle (2019)
Endocannabinoid-like lipoamines may have hitherto unrecognized roles in the metabolic side-effects associated with chemotherapy, with the N-acyl glycine subfamily in particular identified as a potential therapeutic target and/or biomarker of anabolic interventions. CBG-based treatments may represent a novel therapeutic option for chemotherapy-induced cachexia, warranting investigation in tumour-bearing cachexia models.